The evolution of therapeutic resistance is a major cause of death for patients with solid 27 tumors. The development of therapy resistance is shaped by the ecological dynamics 28 within the tumor microenvironment and the selective pressure induced by the host 29 immune system. These ecological and selective forces often lead to evolutionary 30 convergence on one or more pathways or hallmarks that drive progression. These 31 hallmarks are, in turn, intimately linked to each other through gene expression 32 networks. Thus, a deeper understanding of the evolutionary convergences that occur at 33 the gene expression level could reveal vulnerabilities that could be targeted to treat 34 therapy-resistant cancer. To this end, we used a combination of phylogenetic clustering, 35 systems biology analyses, and wet-bench molecular experimentation to identify 36 convergences in gene expression data onto common signaling pathways. We applied 37 these methods to derive new insights about the networks at play during TGF-β-38 mediated epithelial-mesenchymal transition in a lung cancer model system. 39
Introduction 51
Mammalian cells respond to external stimuli through a coordinated system of 52 signaling and gene expression circuitry. The inputs to this system are often the 53 ligands for receptors, which initiate signaling cascades that ultimately lead to 54 changes in gene expression. A cell can receive, process, and integrate multiple 55 simultaneous inputs and respond to them with a coordinated phenotypic 56 response [1, 2] . 57
Deregulation of the cellular signaling/response circuitry is a fundamental 58 theme in cancer at both the tissue and single-cell levels. Indeed, deregulated 59 intracellular signaling/gene expression circuitry is fundamental to many cancer 60 hallmarks [3] , including sustaining proliferation [4, 5] , evading growth 61 suppression [5] , inducing angiogenesis [5] , tumor-promoting inflammation [5] , 62 invasion [6] , and metastasis [7] [8] [9] . 63
One well-studied signaling/expression circuit that is frequently 64 dysregulated in cancer is the transforming growth factor β (TGF-β)/SMAD axis. 65
The TGF-β/SMAD axis is a critical developmental pathway that controls 66 differentiation and proliferation [10] . TGF-β/SMAD signaling is also important in 67 wound healing and fibrosis (reviewed in [11, 12] ). One of the major phenotypic 68 outputs of TGF-β/SMAD signaling is the phenotypic switch from an epithelial to a 69 mesenchymal state, known traditionally as epithelial-mesenchymal transition 70 (EMT) (reviewed in [13] ). In the context of cancer, TGF-β-mediated EMT 71 promotes downregulation of cell-cell adhesion and upregulation of migration and 72 invasion [14, 15] . This pro-invasive phenotype is usually activated at the expense 73 of proliferation [15, 16] : TGF-β induces potent cell cycle arrest through SMAD-74 mediated transcriptional activation of the cell cycle repressor, p21 [17] . TGF-β 75 also reprograms cellular metabolism [18] and induces autophagy [19]-a process 76 in which a cell self-digests its proteins and organelles. In addition to its cell 77 autonomous role in promoting invasiveness, TGF-β also acts non-cell 78 autonomously to create a tumor microenvironment more permissive to tumor 79 growth [20, 21] . These mechanisms can often drive resistance to chemotherapy 80 and multiple targeted therapies [22, 23] . 81 However, the abovementioned effects of TGF-β/SMAD-induced EMT are 82 typically studied in isolation with focus on a few nodes of the pathway, hence 83 neglecting the effects of crosstalk among multiple signaling pathways. Such 84 crosstalk can often generate feedback loops with nonlinear dynamics, giving rise 85 to emergent, complex, and non-intuitive behavior [24] . Hence, a systems biology 86 approach integrating computational and experimental components can be 87 essential to elucidating the dynamics of underlying interconnected cellular 88 circuitry and identifying the fundamental organizational principles driving tumor 89 progression [25] . Here we used such an approach, incorporating multiple systems 90 biology tools to analyze the dynamics of TGF-β-mediated EMT and to 91 experimentally validate the computationally-derived insights (Figure 1) . 92
Cancer progression is an evolutionary process of selection over time [26, 93 27] . Therefore, we postulated that tools developed for tracing evolutionary 94 histories may provide new insights. One of the most commonly-used methods of 95 inferring ancestral relationships is phylogenetics. Phylogenetics uses a data 96 matrix of character states to infer evolutionary relationships between groups 97 [28] . Although phylogenetics was originally developed to reconstruct ancestral 98 relationships between species, phylogenetic inference has also been applied to 99 diverse data sets for which no underlying ancestral relationships exist, such as 100 geography, linguistics, or astrophysics [28] . 101
Given the flexibility of phylogenetics as a clustering tool for multiple data 102 types and contexts, we hypothesized that analysis of time-course gene expression 103 data could provide crucial information about how circuits are integrated to lead 104 to a given phenotype. We identified a convergence of gene expression data on 105 amine metabolism pathways following TGF-β-induced EMT, and validated up-106 regulation of ammonia production using wet bench experimentation. 107
Interestingly, we also identified ATG16L1, a regulator of autophagy, as a central 108 node in an ammonia production gene network, suggesting connections between 109 elevated amine metabolism, EMT, and autophagy. ATG16L1 was also found to be 110 upregulated during TGF-β-induced EMT. Finally, using high throughput drug 111 screens, we showed that siRNA-mediated inhibition of the autophagy regulator, 112 ATG16L1, rescued TGF-β-mediated chemo-resistance. Together, this iterative 113 combination of systems-based analyses and experimental validations suggests 114 that TGF-β-mediated EMT converges on a gene expression network to induce 115 autophagy and altered metabolism that can be therapeutically targeted to 116 overcome chemoresistance. To test the feasibility and effectiveness of using phylogenetics as a 129 clustering tool to analyze gene expression data, we tested if phylogenetic trees 130 could recapitulate the temporal order of gene expression data collected at 131 different time points. To do this, we constructed dendograms from publicly-132 available microarray data for immortalized prostate cells collected every 10 133 passages from 0 to 80 passages (GSE23038, [29] ). 134
We first used distance-based trees to infer temporal relationships among 135 the samples. We first used distance-based trees to infer temporal relationships 136 among the samples. Distance-based trees use a data matrix comprised of gene 137 expression values as a continuous variable without the need for binning gene 138 expression data into categorical variables of being upregulated, unchanged, and 139 downregulated. Distance-based construction of a rooted tree with root at passage 140 0 produced a tree topology that, with the exception of passage 70, clustered 141 samples according to their temporal order from passage 10 to 80 (Figure 2A) . 142
We also analyzed GSE23038 [29] using maximum-likelihood and 143 parsimony phylogenetics methods. The raw data matrix was converted into three 144 character states based on a neutral evolution model, JC69, before being used as 145 input for these two methods of tree construction. Importantly, for all three 146 methods, trees constructed using gene expression data recapitulated the known 147 temporal structure of the data with robust bootstrap support (Figure 2A -C, 148 bootstrap values indicated above branches). A comparison of the three cladistical 149 methods with clustering revealed that hierarchical clustering was unable to 150 accurately reconstruct the temporal order of passages (Figure 2D-E) . 151
Similarly, we performed phylogenetic clustering on additional data sets 152 where samples had been analyzed longitudinally, including GSE17708 [30], 153 microarray data from A549 lung adenocarcinoma cells treated with TGF-β over a 154 period of 72 hours, and GSE12548, microarray data from human ARPE-19 retinal 155 pigment epithelium cells treated with TGF-β and TNF-α over 60 hours [31] . For 156 both of these data sets, phylogenetic clustering reconstructed the temporal order 157 of treatments with strong bootstrap support (Figure 3A and B) . 158
159
Analyzing dynamics of TGF-β treatment through visualization of tree structure 160 reveals two distinct temporally resolved clades 161 A major advantage of clustering is its ability to easily visualize 162 relationships between large data sets and to derive novel useful insights. For 163 example, re-analysis of microarray data from A549 cells treated with TGF-β over 164 72 hours (GSE17708) revealed two distinctive patterns in the resulting 165 phylogenies. First, early time points (0-8 hours) were haphazardly organized in 166 clades and sub-clades, where replicates of samples were admixed, indicating that 167 phylogenetic analyses were not able to provide a clear signal based on the 168 expression data that would predict timing of treatment ( Figure 4A) . Second, the 169 later time points (≥8 hours) were well resolved, suggesting the presence of a 170 clear signal emerging in the gene expression data following long term treatment 171 with TGF-β ( Figure 4A) . 172
Consistent with a convergence of signal at later time points, RT-qPCR 173 analysis of the epithelial marker, E-cadherin, and the mesenchymal marker, 174 vimentin, demonstrated that E-cadherin suppression and vimentin activation 175 were not apparent until this bifurcation of early admixed time-points vs. resolved 176 late time-points ( Figure 4B) . Likewise, our time lapse imaging analysis of growth 177 rate between vehicle-treated and TGF-β-treated A549 cells showed that 178 differences in growth rate between the two conditions were not observed until 179 ~72 hours after the initiation of treatment (Figure 4C) , consistent with reports 180 demonstrating that EMT induces cell cycle arrest [32, 33] . These experimental 181 results suggest that the timing of both gene expression and phenotypic traits 182 associated with EMT are consistent with the convergence of an emerging signal at 183 late time points within the dendograms. 184
Next, we extracted genes that were differentially expressed across the two 185 major clades of early and late treatment times. Pathway analysis of these genes 186 showed that multiple amine-metabolism pathways were significantly altered 187 during TGF-β treatment (Figure 4D) . To experimentally test if ammonia 188 metabolism was altered during TGF-β treatment, we performed ammonia 189 production assays on A549 cells. Importantly, we found that ammonia production 190 was altered significantly upon TGF-β treatment at later time points, with little 191 change in ammonia production during earlier time points ( Figure 4E) . Together, 192 these analyses demonstrated the utility of simple visualizations, such as 193 phylogenetic trees and clustering dendograms, to yield new testable hypotheses. 194
195

Gene expression networks couple ammonia production to autophagy 196
Previous research has identified a connection between up-regulation of 197 ammonia production and induction of autophagy (7). Based on this connection, 198
we tested if TGF-β-induced EMT led to an increase in autophagy markers. In 199 support of this hypothesis, TGF-β treatment led to upregulation of autophagy 200 markers LC3A/B and ATG16L1 (Figure 5A) . To better understand the 201 connections between ammonia production and autophagy, we used Cytoscape to 202 construct gene regulatory networks related to amine metabolism genes and 203 autophagy regulators. We constructed gene networks that included the ammonia 204 production genes identified by the pathway analysis, along with the autophagy 205 markers LC3A/B and ATG16L1 that we identified in our western blots to be 206 activated upon TGF-β treatment. Although we found few gene-gene interactions 207 among amine metabolism genes alone (Figure 5B) , when we added the 208 autophagy regulator ATG16L1 to this network, it connected the entire set of 209 previously-isolated amine metabolism sub-networks ( Figure 5C ). LC3A/B was a 210 node in the ATG16L1 network (Supplementary File 4) . Our results suggest that 211 TGF-β-mediated EMT is associated with increased amine production and 212 upregulation of autophagy. It remains to be tested in this system if the ammonia 213 production induces autophagy, as has been demonstrated previously in both 214 yeast and mouse embryonic fibroblasts [34] , or if TGF-β-induced autophagy 215 upregulation leads to more ammonia. However, our results demonstrate a 216 connection between TGF-β-mediated EMT, altered amine production, and 217 upregulation of autophagy. 218 219
Autophagy inhibition re-sensitizes cells to TGF-β-induced chemoresistance 220
Our data revealed that TGF-β-induced EMT leads to ammonia production and 221 upregulation of autophagy. Interestingly, both EMT and autophagy are known to be 222 involved in chemoresistance. EMT can drive chemoresistance in multiple cancers [35-223 38] . Likewise, autophagy is a pro-survival mechanism in response to cellular stresses, 224 such as hypoxia and nutrient deprivation, and is increasingly implicated in resistance to 225 cancer treatments [39, 40] . Integrating our observations with these reports, we 226 hypothesized that EMT-induced drug resistance is mediated, at least in part, by elevated 227
autophagy. 228
To test this hypothesis, we used high-throughput drug screens of 119 FDA-229 approved small-molecule anti-cancer agents. To do this, we first tested if TGF-β-230 mediated EMT led to chemoresistance. We screened A549 cells treated with either 231 vehicle or TGF-β and plated at both low and high density. After 72 hours of incubation 232 with each drug, the overall cell viability was analyzed with CellTiterGlo. We first 233 performed quality control analyses of the screens. Linear regression of the empty wells 234 and DMSO-treated wells showed virtually no relationship between the CellTiterGlo 235 value and the position on the plate when comparing the same plate setup across 236 multiple plates (R 2 = 0.0862), suggesting that the screen results did not suffer from 237 plate effects (Supplementary Figure 1) . In contrast, the correlation coefficients in 238 drug-containing wells were greater than 0.8 between high and low cell density for both 239 vehicle-and TGF-β-treated conditions, suggesting high reproducibility across replicate 240 plates, when drug is present in the well (Supplementary Figure 1) . 241
Given the lack of apparent plate effects and strong reproducibility between 242 replicate screens, we investigated whether TGF-β induced chemoresistance. Consistent 243 with our hypothesis, TGF-β treatment increased resistance to 60% (71/119) of the 244 compounds tested, as evaluated by an increase in CellTiterGlo absorbance as compared 245 to vehicle-treated control wells (Figure 6A) . Analysis of these compounds by pathway 246 targets showed that TGF-β induced resistance to both broad spectrum chemotherapies, 247 such as microtubule-targeting agents and topoisomerase inhibitors, as well as multiple 248 targeted therapies, including those against HER2 and EGFR (Figure 6B) . 249
Next, to investigate the importance of autophagy in promoting TGF-β-induced 250 therapy resistance, we performed siRNA-mediated knockdown of ATG16L1, the 251 autophagy marker we identified as upregulated in TGF-β treated cells. We first tested 252 knockdown efficiency using four independent siRNAs and selected by western blot 253 analysis siRNA_1 for subsequent drug screens (Figure 6C) . We then screened A549 254 with the same 119 drugs +/-TGF-β and treated with either a non-silencing siRNA or 255 siRNA_1 targeting ATG16L1. Remarkably, ATG16L1 knockdown re-sensitized cells to 256 29/71 (41%) of drugs for which TGF-β treatment led to increased resistance ( Figure  257 6D). Interestingly, these drugs included current standard of care therapies for small-cell 258 lung cancer (SCLC), doxorubicin and topotecan, as well as anti-VEGFR therapies, 259 regorafenib and axitinib, both of which have shown promising clinical benefits in early 260 stage clinical trials against advanced non-small-cell lung cancer (NSCLC) [41, 42] , and 261 cabozantinib, a tyrosine kinase inhibitor that has shown efficacy along or in 262 combination with erlotinib in treatment of EGFR wild-type NSCLC patients [43] . 263
Analysis by pathways showed that autophagy inhibition on average re-sensitized cells 264 to multiple targeted therapies, including c-MET, c-RET, FLT3, TAM2, and dihydrofolate 265 reductase (DHFR) (Figure 6E) . Together, our results support the hypothesis that TGF-266 β-mediated therapy resistance is driven, in part, by autophagy, suggesting the potential 267 use of autophagy inhibitors as a concurrent or adjuvant therapy to counter resistance. 268
To determine if ATG16L1 was related to clinical outcomes, we analyzed 269 ATG16L1 expression in gene expression data sets from patient tumors. Analysis of 270
Kaplan Meier curves showed that low ATG16L1 expression is prognostic for improved 271 overall survival in patients with lung and clear cell renal cancer (Figure 7A-C) and 272 improved relapse-free survival in patients with colorectal cancer (Figure 7D) . It is also 273 worth noting that high ATG16L1 was prognostic for improved disease-free survival in 274 breast cancer (Figure 7E) Here, we combined methods rooted in evolutionary theory, such as 289 phylogenetic inference, with pathway and network analyses, as well as 290 experimental techniques, to yield new insights. By taking this novel approach to 291 analyze a well-established system-TGF-β-induced EMT-we identified 292 mechanisms of therapy resistance. Specifically, we found that EMT leads to 293 increased production of intracellular ammonia. Ammonia is a by-product of 294 protein breakdown and serves an important function in maintaining homeostasis 295 in electrolyte concentration [51] . Recent evidence, however, also suggests that 296 ammonia production is involved in regulating autophagy and pro-survival circuits 297 that contribute to chemoresistance [34, 52] . Importantly, autophagy can lead to 298 increased aggressiveness in cancer, perhaps as an adaptive response to cellular 299 stress. In our present study, downregulation of autophagy partially reversed 300 EMT-induced therapy resistance, suggesting the potential benefits of concurrent 301 uses of autophagy inhibitors with standard-of-care therapies. 
Phylogenetic reconstructions from gene expression data 370
Distance-based dendogram analyses were performed by constructing a 371 distance matrix calculated based on the entire microarray data set for each data 372 set to be analyzed, using the genes as the characters, the raw expression value for 373 each gene as the character states, and the samples as the taxa. The Neighbor 374
Joining method [60] was used for reconstructing phylogeny with distance 375 matrices. To perform analysis based on maximum-likelihood (ML) and 376 parsimony, the continuous gene expression data was converted into categorical 377 variables. For example, for GSE23038, we used the passage 0 sample as an 378 'outgroup', and converted the gene expression data for all other samples into 379 either up-regulated, down-regulated, or constant relative to passage 0. The 380 reliability of the parsimony method is generally considered to increase with an 381 increasing number of informative characters [61] [62] [63] . Therefore, cut-off 382 thresholds of up-and down-regulation were determined by calculating the 383 maximum number of informative sites given different cut-offs, and a threshold 384 was selected that provided the highest number of informative sites in each data 385 set. ML and parsimony analyses were then performed based on converted data. 386 ML analysis after data conversion was performed online on a free phylogeny 387 platform PhyML 3.0 (14) TGF-β (R&D Systems). Briefly, A549 cells were dispensed using liquid handling 397 into 384 well plates with no drug, DMSO, or 1 μM drug at cell plating densities of 398 250 and 1000 cells/well. Plates were incubated at 37°C, and cell viability was 399 assayed by CellTiterGlo after 72 hours. Relative drug resistance or sensitivity was 400 calculated as the fold change difference in CellTiterGlo value between vehicle-401 treated and TGF-β-treated wells. To perform the screen in the context of 402 ATG16L1 knockdown, 20 nM siRNA targeting ATG16L1 was delivered to A549 403 cells by reverse transfection using RNAiMax and incubated at 37°C for 24 hours. 404
After 24 hours, the drug screen was performed -/+ TGF-β as described above. 
